New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency
By Dr. Matthew Watson
agency wants to recruit major biotech and venture capital firms to
help provide tens of millions of dollars in research awards to
California enterprises.
partnerships in a relatively new, $80 million, business-friendly program that is aimed at pushing therapies into the
marketplace. The recruitment plan will come before the agency's governing board at its meeting next Wednesday in San Diego.
special relationship with the state agency, including early input
into concept funding proposals prior to their being presented to the
agency's governing board. The “industry collaborators” will also
be able to attend agency workshops and meetings involving
hundreds of grant recipients. Presumably other, non-collaborating
firms would be barred.
special event-hosting arrangements aimed at creating more
collaborations and posting of information from the selected
collaborators on the CIRM website.
initiative would be limited to biotech and pharmaceutical firms with
a market capitalization of at least $500 million and “qualified
venture capital firms.” The document did not define what a
“qualified a venture capital firm” is. The document also appeared
to bar participation of privately held firms because of the “market
capitalization” criteria, which typically uses a formula involving
publicly traded shares.
counsel and vice president, business development, said in a statement
provided to the California Stem Cell Report,
“This is aimed at trying to jump
start the creation of the partnerships that are required to satisfy
the commercial validation requirements of the Strategic Partnership
Funding Initiative so that timelines are better synced-up as between
our review and approval cycles for the Strategic Partnership RFAs and
the lengthy time required for investors to conduct due diligence and
negotiate an agreement with prospective applicants to Strategic
Partnership RFAs. CIRM's independent review and approval
remains the same and is wholly independent. While there may be input
given to a particular RFA it only at the high level concept stage and
of course CIRM has no obligation to agree. In the context of the
Strategic Partnership awards, CIRM wants to fund innovative high
quality science that has attracted additional investors.
Investors will help leverage CIRM fund and will be an important
source of future funding to further the project.”
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ZtmnBmRh5K0/new-ties-to-big-pharma-and-venture.html
Stem Cell Therapy
Comments Off on New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency |
August 25th, 2013
A $2 Million Bill: Outside Contracting by California Stem Cell Agency
By Dr. Matthew Watson
agency this week posted a list of its outside contractors, who range
from a a $25,000 stem cell licensing consultant to a $550,000-a-year law firm.
million during 2013-14 on outside contracting, down from $2.9 million
in 2012-13. This week's report covers the 2012-13 year.
largest item in the agency's budget, which is slated to spend $17.4
million this fiscal year for operational expenses, up 5 percent
from last year's spending. The largest amount, $12.2 million, goes
for salaries and benefits. (For more on the budget, see here, here
and here.)
firm of Remcho, Johansen & Purcell of San Leandro, Ca., which had
the $550,000 contract. CIRM, as the agency is known, reported that Remcho came in under
budget by $95,595. That contrasts to some previous years when the
firm, which has represented the stem cell agency since its inception,
required additional cash on top of its original contract. James
Harrison of the Remcho firm is its face at the agency and is
designated as the outside counsel to the agency's governing board. In
all, the agency is slated to spend $2.2 million on legal expenses,
including in-house work.
contractor. He was paid only $13,125 on his $25,000 contract during
2012-13. It is unclear whether he will be paid the $11,875 balance.
Earp was chief patent counsel and senior vice president for business
development for Geron before it dropped its stem cell program. Earp was heavily involved in the $25 million loan that CIRM made to Geron in 2011. In
February 2008, he testified before CIRM about its then proposed loan
program.
$200,000 to the AlphaMed Press of Durham, N.C., as seed funding for a
stem cells translational journal, $156,434 to Hyatt Hotels for the
meeting of CIRM grant recipients, $250,000 to Kutir Corp. of Newark, Ca., for
informational technology services and $290,000 to the Mitchell
Group of Woodland Hills, Ca., also for information technology services.
presented to the CIRM governing board at its meeting next week. The
list does not usually trigger any significant discussion.
Source:Stem Cell Therapy
Comments Off on A $2 Million Bill: Outside Contracting by California Stem Cell Agency |
August 25th, 2013
California Stem Cell Agency Spending: Where the Money Is Going
By Dr. Matthew Watson
 |
| Analysis of CIRM funding by Pat Olson, executive director of CIRM scientific activities July 2013 |
have committed $472 million to translational research – a key to
commercializing stem cell therapies – if it awards the full $70
million in new grants and loans slated to come before its governing
board next week.
about 17 percent of its funding so far, according to an analysis last
month by Pat Olson, the agency's executive director of scientific activities. The
largest percentage of the agency's cash, however, will be going for
“development” – 35 percent or $970 million. Olson defined
“development” as “essentially our IND enabling, our
preclinical development programs and our clinical development
programs.”
or about $469 million with buildings and facilities taking up $443
million or 16 percent. Training and career development has consumed
about 15 percent or $414 million.
$577 million in funds that have been allocated but not yet awarded.
Another $491 million is “concept approved” but also not awarded.
The agency's governing board could change those allocations or
withdraw approval of concepts, although it has not yet shown signs
that it might do so.
new grants in 2017 and is examining the possibility of generating
more cash through some sort of public-private partnership. To develop
support for continued funding, the agency is under pressure to
generate results that will resonate with the public and potential
private funding sources. Those results are most likely to come from
a late stage translational/clinical trial effort.
(An earlier version of this item incorrectly said that the agency would run out of money for new grants in 2013. The correct year is 2017,.)
Source:Stem Cell Therapy
Comments Off on California Stem Cell Agency Spending: Where the Money Is Going |
August 25th, 2013
Flim-Flam Stem Cell Artists Targeted by CIRM
By Dr. Matthew Watson
joined with other prestigious stem cell organizations to help put a
stop to the flim-flam artists that prey on desperate people by
promising miracle cures from stem cell treatments.
patients should consider when making treatment decisions.”
education communications officer and author of the blog item, said
the document addresses one of his special concerns: Internet “ads
that come up on web searches and seem to be offering everything to
everyone.”
automatically by Google.
Source:California Stem Cell Researchers to Receive $70 Million Next Week
By Dr. Matthew Watson
scheduled to give away $70 million next week as it moves forward on
its efforts to turn research into cures.
projected to be awarded in the early translation round. The awards will range up to $3.5 million over a three year period. The round was open to
both businesses and academic institutions. Collaborators from Germany
were involved, although funding for research in that country is not provided by the state stem cell agency.
the $3 billion agency's governing board at its Aug. 28 meeting in La Jolla. After next week's awards, the agency, which is known as CIRM, will have about $500
million left to hand out before cash for new awards runs out in 2017.
The agency is currently examining ways to continue its awards with
some sort of public-private partnership.
proposed announcement for a CIRM/industry co-funding agreement. No
further details on that program were available early today on the agenda.
Other matters to be considered include final approval of the changes
in the agency's IP regulations, appointment of new members to the
grant review group and the latest report on the outside contracts
held by the agency. Details on those matters are yet to be posted by
the agency.
co-vice chairman of the agency, is also scheduled. The board will
additionally meet behind closed doors to evaluate the performance of
CIRM President Alan Trounson.
carry more information on the meeting as it becomes available.
for the meeting, other locations where the public can take part in
the meeting are in Menlo Park and Duarte. Specific addresses can be
found on the agenda.
Source:Stem Cell Therapy
Comments Off on California Stem Cell Researchers to Receive $70 Million Next Week |
August 25th, 2013
Sizzling Penny Stocks – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release)
By Dr. Matthew Watson
Sizzling Penny Stocks - Generex Biotechnology Corporation (OTCMKTS:GNBT ... SBWire (press release) Generex Biotechnology Corporation (www.generex.com) (GNBT) announced publication of follow up studies from a Phase I clinical trial of its immunotherapeutic agent AE37 in patients with prostate cancer. The Phase I study demonstrated that the compound ... Stocks on the Move-Generex Biotechnology Corporation (OTCMKTS: GNBT ...Techsonian |
Uncategorized
Comments Off on Sizzling Penny Stocks – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release) |
August 24th, 2013
‘Customize’ your stem cell therapy
By JoanneRUSSELL25
The bad news: "Stem cells by themselves do not work."
The good news: "Stem cells by themselves do not work."
Take it from the doctor who has treated 5,000 patients with stem cell therapy, a doctor who is himself a cancer survivor. Thirteen years ago, Dr. Sam Bernal - oncologist, chemist, molecular biologist, lawyer, professor and lecturer, among other things - was a cancer patient who thought he was at death's door. Using stem cells sourced from his bone marrow and peripheral blood, he overcame the disease and has since become an advocate of living fit, living well in order to look good.
Dr. Bernal, who divides his time between Los Angeles, Prague, Makati, and Germany, was a pioneer in stem cell research in the Philippines early on in his career, for which he was cited when he received the Presidential Award for Outstanding Filipinos Overseas from President Benigno S, Aquino III in 2012.
At a recent meeting with journalists, Dr. Bernal hurled the challenge: "What do you need stem cell therapy for if you eat well, sleep soundly, exercise regularly, don't smoke, have a positive attitude, and know how to live in the moment as you gaze at a painting and get a thrill out of small things like that?"
Not only is the doctor a passionate advocate of living the good life, the simple life, and, yes, Argentine tango - "It's better than boring exercises at the gym!" - he believes in healthy eating. "I brought a group of European friends to Manila and they were flabbergasted at our vegetable dishes - laing, gising-gising, buko juice - our simplest food was gourmet cuisine to them!"
No, he's not a vegetarian, but a "flexitarian."
But if stem cells - the body's own master and repair cells - aren't the key to staying young, what is? The holistic approach works best, according to the doctor, stating that the procedure should be recommended by doctors "on a case by case basis." In effect, the doctor prescribes "customizing your stem cell therapy."
In his book, molecular biology provides the battleground from which to attack the afflictions of aging that signal a desire or need to repair or replace one's stem cells. Speaking of books, Dr. Bernal continues to teach at Harvard, Ateneo, UST, and Medical City as a component of his mission to spread the benefits of technology transfer, which is the vision of his company, GlobeTek Science Foundation (based in Makati).
Excerpt from:
‘Customize’ your stem cell therapy
Uncategorized
Comments Off on ‘Customize’ your stem cell therapy |
August 24th, 2013
Stem cell therapy treats animal ailments, vets see improvement – Video
By LizaAVILA
Stem cell therapy treats animal ailments, vets see improvement
Stem cell therapy is typically tied to controversy but now, some Southern Arizona veterinarians are turning to a different form of the cutting edge treatment...
By: kgun9
See the original post here:
Stem cell therapy treats animal ailments, vets see improvement - Video
Uncategorized
Comments Off on Stem cell therapy treats animal ailments, vets see improvement – Video |
August 21st, 2013
Bearded Collie OA BEFORE Stem Cell Therapy – Video
By daniellenierenberg
Bearded Collie OA BEFORE Stem Cell Therapy
By: MediVet Arizona
Original post:
Bearded Collie OA BEFORE Stem Cell Therapy - Video
Uncategorized
Comments Off on Bearded Collie OA BEFORE Stem Cell Therapy – Video |
August 20th, 2013
2 months after stem cell therapy – Video
By Sykes24Tracey
2 months after stem cell therapy
Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now.
By: Jacek Kozlowski
More here:
2 months after stem cell therapy - Video
Uncategorized
Comments Off on 2 months after stem cell therapy – Video |
August 20th, 2013
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 – DOH
By raymumme
By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM
InterAksyon.com The online news portal of TV5
MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday.
Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits.
Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH).
Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes.
"This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added.
Among the DOH guidelines are:
Ona conceded that there are only a limited number of medical conditions in which stem cell therapy may be indicated.
Others are claims that should be taken with a grain of salt, he said.
The rest is here:
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 - DOH
Uncategorized
Comments Off on REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 – DOH |
August 20th, 2013
Docs seek stop to expensive, experimental stem cell therapy
By NEVAGiles23
By Philip C. Tubeza Philippine Daily Inquirer
MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.
Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.
The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.
Cease and desist
We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.
The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.
The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.
Lack of evidence
Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.
The rest is here:
Docs seek stop to expensive, experimental stem cell therapy
Uncategorized
Comments Off on Docs seek stop to expensive, experimental stem cell therapy |
August 20th, 2013
Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy
By raymumme
CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications.
This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing.
The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition.
"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times." The horse is an FDA approved model species for athletic injuries.
Dr Casey is a Veterinary graduate from Massey University (BVSc, 1988), and graduate from the University of California in 1992 with a Doctor of Philosophy (PhD, Comparative Pathology). During his time in the United States he also completed an Equine Surgical Internship at Hagyard-Davidson and McGee, Lexington, Kentucky, followed by a three year residency programme in Equine Reproduction, with a minor in Equine Medicine at UC Davis. In 1992, 1993, and 1994 he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.
Since 2011, Dr Casey has been chief scientific consultant to a public company in the USA - Therapy Cells Inc (TCEL on the OTC Market).
This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue, effectively by-passing the need for Stem Cell treatment.
"The financial and curative potential of this biotechnology platform is immediately obvious," states Dr Casey. "When we talk about regenerative procedures, the ability to rejuvenate tissues and organs with cultivated natural cell therapy, it's easy to understand how enormous the opportunity and the impact will be. The awarding of this US Patent for our transformational science is a significant milestone in the steps we have been taking to get our therapies to market."
Contact:
Contact: Patrick Casey
See the article here:
Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy
Uncategorized
Comments Off on Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy |
August 20th, 2013
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine …
By NEVAGiles23
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.
MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.
About BioTime, Inc
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:
Additional information about BioTime can be found on the web at http://www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.
Read the original post:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...
Uncategorized
Comments Off on BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine … |
August 19th, 2013
What’s Stem Cell Therapy Dr Bill Johnson Has Answers – Video
By Sykes24Tracey
What #39;s Stem Cell Therapy Dr Bill Johnson Has Answers
for more information go to... http://www.innovationstemcellcenter.com More useful info below... Drapeau #39;s theory that Adult Stem Cells are nothing less than the hum...
By: Mark Khan
Excerpt from:
What's Stem Cell Therapy Dr Bill Johnson Has Answers - Video
Uncategorized
Comments Off on What’s Stem Cell Therapy Dr Bill Johnson Has Answers – Video |
August 19th, 2013
Stem Cell Therapy: Where’s the Evidence? – Video
By Sykes24Tracey
Stem Cell Therapy: Where #39;s the Evidence?
Dr. Tony Dans of the University of the Philippines College of Medicine discusses dilemmas in research and regulation of stem cell therapy in the Philippines....
By: Antonio Dans
See original here:
Stem Cell Therapy: Where's the Evidence? - Video
Uncategorized
Comments Off on Stem Cell Therapy: Where’s the Evidence? – Video |
August 19th, 2013
FDA hearing on stem cell therapy set on Friday, Aug. 23
By JoanneRUSSELL25
By: Jet Villa, InterAksyon.com August 18, 2013 5:02 PM
REUTERS FILE PHOTO
InterAksyon.com The online news portal of TV5
MANILA, Philippines - The Food and Drug Administration (FDA) will conduct on Friday, August 23, a public hearing on the regulation of stem cell therapy in the country.
The FDA said the public hearing is scheduled from 3 p.m. to 5 p,m, at the Audio-Visual Room, 3rd floor, Annex Building, FDA office on Civil Drive in Alabang Muntinlupa.
The purpose of the hearing is to discuss the regulation of stem cell therapy, the stem cell products, and the health facilities that are offering the service in the court, it said.
The FDA also established an online reporting system to document adverse events linked to human cells, tissues, and cellular- and tissue-based products such stem cell therapies acquired in any facility.
The agency said those who experienced any untoward event or side effect or treatment failures after undergoing stem cell procedures can report through FDA website at http://www.fda.gov.ph under eReport and Adverse Drug Reaction, Report section.
E-mails may also be sent toreport@fda.gov.ph.
All consumers are assuredthat all information given will be treated with utmost confidentiality.Contact details are needed in case of a need for follow-up and validation.However, anonymous reports will still be accepted, the FDA added.
Read more:
FDA hearing on stem cell therapy set on Friday, Aug. 23
Uncategorized
Comments Off on FDA hearing on stem cell therapy set on Friday, Aug. 23 |
August 19th, 2013
Genetic Engineering Produces A Genuine Monstrosity – Forbes
By Dr. Matthew Watson
Genetic Engineering Produces A Genuine Monstrosity Forbes Activists have warned for decades that genetic engineering would create some sort of monstrosity like Dr. Frankenstein's creature. It turns out they were right: Government regulation has run amok and threatens advances in agriculture. USDA's existing ... |
Uncategorized
Comments Off on Genetic Engineering Produces A Genuine Monstrosity – Forbes |
August 18th, 2013
Genetic engineering project begins with glow-in-the-dark rabbits, but it could … – MedCity News
By Dr. Matthew Watson
 ABC News | Genetic engineering project begins with glow-in-the-dark rabbits, but it could ... MedCity News The point of the flashy genetic engineering is not to give pet store owners a new product to hawk, but rather to confirm that the techniques researchers use to transfer genes into a genome are working. And in many cases, the greater goal is to develop ... UNIVERSITY OF HAWAII AT MANOAStuff.co.nz A Gene That Was Not Originally in Animals Now ExistsFrench Tribune |
Uncategorized
Comments Off on Genetic engineering project begins with glow-in-the-dark rabbits, but it could … – MedCity News |
August 18th, 2013
Ghana to tap into genetic engineering – Biochemist – Ghana Business News
By Dr. Matthew Watson
 Ghana Business News | Ghana to tap into genetic engineering – Biochemist Ghana Business News Dr Yaa Difie Osei, a biochemist and molecular biologist, has said the country was positioning itself to tap into the benefits of modern biotechnology and genetic engineering for guaranteed food security. She said structures including institutional and ... |
Uncategorized
Comments Off on Ghana to tap into genetic engineering – Biochemist – Ghana Business News |
August 18th, 2013